Modified-Release Oral Minoxidil for Stable Serum Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, particularly male and female pattern baldness, do not provide sustained and controlled release of minoxidil, leading to variable pharmacokinetic profiles and potential adverse effects.
Innovation Solution
A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, minimizing adverse effects and optimizing hair regrowth treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional minoxidil formulations are used, then hair loss treatment is provided, but the drug release is not sustained and controlled, leading to variable pharmacokinetic profiles
Solution Approach 1:
The minoxidil formulation is segmented into multiple release phases using different polymer matrices and coating systems. The tablet contains immediate-release minoxidil core surrounded by sustained-release polymer layers, creating distinct release stages that collectively provide consistent pharmacokinetic profiles over extended periods.
Solution Approach 2:
The invention changes the physical and chemical parameters of minoxidil delivery by using pH-sensitive polymers, enteric coatings, and controlled-release matrices. These parameter changes enable sustained release over 24 hours or longer, transforming the short-acting conventional formulation into a long-acting controlled-release system with reliable pharmacokinetics.
2Productivity
If conventional minoxidil formulations are used, then hair regrowth treatment is provided, but adverse effects occur due to uncontrolled release
Solution Approach 1:
The controlled-release formulation implements periodic drug delivery through rhythmic release patterns. The tablet releases minoxidil in controlled pulses or sustained steady-state concentrations over 24 hours, avoiding the sharp peaks and valleys of conventional dosing. This periodic action maintains therapeutic levels while minimizing adverse effects associated with high peak concentrations.
Solution Approach 2:
Polymer matrices and coating systems serve as intermediaries between the minoxidil drug and the biological system. These intermediary materials control the rate and pattern of drug release, buffering the biological system against harmful fluctuations in drug concentration while ensuring adequate therapeutic delivery for hair regrowth.
3Speed
If immediate release formulations are used, then rapid drug availability is achieved, but serum concentrations fluctuate significantly
Solution Approach 1:
The formulation incorporates preliminary action through pre-designed release mechanisms that begin controlling drug release immediately upon ingestion. The tablet structure is pre-engineered with immediate-release components for rapid initial availability followed by built-in sustained-release mechanisms that automatically activate, providing both speed and stability without requiring external intervention.
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.